Atropos Health vs OpenEvidence
These two look like competitors and are actually sequential, which is the most useful thing a buyer can know about them. OpenEvidence searches what has been published and returns a cited answer in seconds. Atropos, spun out of Stanford's Green Button project, generates evidence that does not exist yet, running a publication grade observational study across a federated network of more than 300 million de identified records to answer the question no trial covers. So the honest framing is that you reach for OpenEvidence when the literature has probably answered this, and for Atropos when you already know it has not. Atropos also holds the better privacy architecture, linking records only at query time rather than pooling them. It publishes no price, no attestation and no trust centre, so the diligence burden sits entirely with the buyer.
- It answers the question the literature cannot: what happened to patients like this one, generated on demand from a federated network the company describes as exceeding 300 million anonymised records rather than retrieved from a paper someone already wrote.
- The privacy architecture is the disclosure. A federated network with nodal de identification links records only at query time rather than assembling a central warehouse, which removes the aggregation risk instead of governing it.
- Output is a publication grade observational study rather than a summary, which means the method is inspectable and the result can be argued with, defended in a committee or submitted.
- Eleven independent studies evaluating this product between 2024 and 2026, identified through a systematic review, against a vendor with no located third party attestation or trust centre at all.
- It is free to verified United States clinicians and takes seconds, where the alternative publishes no price of any kind, no unit and no indication of whether it is sold per query, per seat or per data source.
- Named partnerships with the New England Journal of Medicine, JAMA and Cochrane, plus web, mobile and Epic embedded delivery, which is the practical answer at the point of care rather than in a research meeting.
Side by Side
| Axis | A Atropos Health |
O OpenEvidence |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These products answer different questions and should not be treated as substitutes: one retrieves and synthesises published evidence, the other generates new observational evidence from real world data. Atropos publishes no pricing of any kind, no security attestation, trust centre or third party certification, and its security language is atmospheric rather than specific.
Observational evidence generated on demand carries confounding and selection risks that a rapid workflow does not remove, so the methodology of each generated study is the thing to review rather than the speed of it. OpenEvidence is funded by pharmaceutical and device advertising alongside its answers, governed by a published policy.